Breast Cancer Clinical Trial
— SOLAR-1Official title:
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Verified date | November 2023 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease.
Status | Completed |
Enrollment | 572 |
Est. completion date | June 9, 2023 |
Est. primary completion date | June 12, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - If female, patient is postmenopausal - Patient has identified PIK3CA status - Patients may be: - relapsed with documented evidence of progression while on (neo) adjuvant endocrine therapy or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease; - relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently; progressed with documented evidence of progression while on or after only one line of endocrine therapy for metastatic disease; - newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy - Patient has recurrence or progression of disease during or after AI therapy (i.e. letrozole, anastrozole, exemestane). - Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by local laboratory and has HER2 negative breast cancer - Patient has either measurable disease per RECIST 1.1 criteria OR at least one predominantly lytic bone lesion must be present - Patient has adequate bone marrow function Exclusion Criteria: - Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment - Patient has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor (pre-treatment with CDK4/6 inhibitors is allowed) - Patient with inflammatory breast cancer at screening - Patients with Child pugh score B or C - Patients with an established diagnosis of diabetes mellitus type I or not controlled type II - Patient has Eastern Cooperative Oncology Group (ECOG) performance status 2 or more - Patient with CNS involvement unless he/she is at least 4 weeks from prior therapy completion to starting the study treatment and has stable CNS tumor at time of screening and not receiving steroids and/or enzyme inducing ant-epileptic medications for brain metastases - Patient has participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer - Patient has a history of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis - Patient who relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease Other protocol-defined inclusion/esclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Argentina | Novartis Investigative Site | Berazategui | Buenos Aires |
Argentina | Novartis Investigative Site | Caba | Buenos Aires |
Argentina | Novartis Investigative Site | La Rioja | |
Argentina | Novartis Investigative Site | Rio Negro | Viedma |
Australia | Novartis Investigative Site | Elizabeth Vale | South Australia |
Australia | Novartis Investigative Site | Melbourne | Victoria |
Australia | Novartis Investigative Site | Wahroonga | New South Wales |
Australia | Novartis Investigative Site | Wooloongabba | Queensland |
Austria | Novartis Investigative Site | Linz | |
Austria | Novartis Investigative Site | Vienna | |
Belgium | Novartis Investigative Site | Bruxelles | |
Belgium | Novartis Investigative Site | Edegem | Antwerpen |
Belgium | Novartis Investigative Site | Jette | Brussel |
Belgium | Novartis Investigative Site | Libramont | |
Belgium | Novartis Investigative Site | Ottignies | |
Belgium | Novartis Investigative Site | Sint Niklaas | Oost Vlaanderen |
Belgium | Novartis Investigative Site | Verviers | |
Brazil | Novartis Investigative Site | Lajeado | RS |
Brazil | Novartis Investigative Site | Natal | RN |
Brazil | Novartis Investigative Site | Sao Jose do Rio Preto | |
Brazil | Novartis Investigative Site | Sao Paulo | |
Brazil | Novartis Investigative Site | Sao Paulo | SP |
Bulgaria | Novartis Investigative Site | Plovdiv | |
Bulgaria | Novartis Investigative Site | Sofia | |
Bulgaria | Novartis Investigative Site | Varna | |
Bulgaria | Novartis Investigative Site | Varna | |
Canada | Novartis Investigative Site | Calgary | Alberta |
Canada | Novartis Investigative Site | Cambridge | Ontario |
Canada | Novartis Investigative Site | Ottawa | Ontario |
Canada | Novartis Investigative Site | Quebec | |
Canada | Novartis Investigative Site | Toronto | Ontario |
Chile | Novartis Investigative Site | Santiago | |
Chile | Novartis Investigative Site | Temuco | Araucania |
Chile | Novartis Investigative Site | Vina del Mar | |
Czechia | Novartis Investigative Site | Hradec Kralove | Czech Republic |
Czechia | Novartis Investigative Site | Prague 8 | |
Czechia | Novartis Investigative Site | Praha 4 | Czech Republic |
Czechia | Novartis Investigative Site | Zlin | Czech Republic |
France | Novartis Investigative Site | Angers 02 | |
France | Novartis Investigative Site | Avignon | |
France | Novartis Investigative Site | Caen | |
France | Novartis Investigative Site | Clermont Ferrand | |
France | Novartis Investigative Site | Creteil | |
France | Novartis Investigative Site | La Roche sur Yon cedex 9 | |
France | Novartis Investigative Site | Le Chesnay | |
France | Novartis Investigative Site | Levallois-Perret | |
France | Novartis Investigative Site | Lyon Cedex 08 | |
France | Novartis Investigative Site | Marseille cedex 20 | Bouches Du Rhone |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigative Site | Nimes | |
France | Novartis Investigative Site | Rouen | |
France | Novartis Investigative Site | Saint-Herblain Cédex | |
France | Novartis Investigative Site | Toulouse | |
France | Novartis Investigative Site | Villejuif Cedex | |
Germany | Novartis Investigative Site | Aschaffenburg | |
Germany | Novartis Investigative Site | Frankfurt | |
Germany | Novartis Investigative Site | Friedrichshafen | |
Germany | Novartis Investigative Site | Hannover | |
Germany | Novartis Investigative Site | Homburg | |
Germany | Novartis Investigative Site | Kiel | |
Germany | Novartis Investigative Site | Leipzig | Sachsen |
Germany | Novartis Investigative Site | Luebeck | Schleswig-Holstein |
Germany | Novartis Investigative Site | Mainz | |
Germany | Novartis Investigative Site | Potsdam | |
Germany | Novartis Investigative Site | Recklinghausen | North Rhine-westphalia |
Germany | Novartis Investigative Site | Rostock | |
Germany | Novartis Investigative Site | Ulm | |
Germany | Novartis Investigative Site | Velbert | |
Greece | Novartis Investigative Site | Athens | |
Greece | Novartis Investigative Site | Athens | |
Greece | Novartis Investigative Site | Thessaloniki | GR |
Hong Kong | Novartis Investigative Site | Hong Kong | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Nyiregyhaza | |
Hungary | Novartis Investigative Site | Szekszard | |
India | Novartis Investigative Site | Mumbai | |
India | Novartis Investigative Site | Nagpur - Maharashtra | Maharashtra |
India | Novartis Investigative Site | Vijayawada | Andhra Pradesh |
Israel | Novartis Investigative Site | Beer-Sheva | |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Petach Tikva | |
Israel | Novartis Investigative Site | Ramat Gan | |
Israel | Novartis Investigative Site | Tel Aviv | |
Italy | Novartis Investigative Site | Ancona | AN |
Italy | Novartis Investigative Site | Aviano | PN |
Italy | Novartis Investigative Site | Chieti | CH |
Italy | Novartis Investigative Site | Meldola | FC |
Italy | Novartis Investigative Site | Milano | MI |
Italy | Novartis Investigative Site | Negrar | VR |
Italy | Novartis Investigative Site | Padova | PD |
Italy | Novartis Investigative Site | Palermo | PA |
Italy | Novartis Investigative Site | Pontedera | PI |
Italy | Novartis Investigative Site | Rionero in Vulture | PZ |
Italy | Novartis Investigative Site | Roma | RM |
Italy | Novartis Investigative Site | Sassari | SS |
Italy | Novartis Investigative Site | Savona | SV |
Italy | Novartis Investigative Site | Torino | TO |
Japan | Novartis Investigative Site | Akashi | Hyogo |
Japan | Novartis Investigative Site | Chuo ku | Tokyo |
Japan | Novartis Investigative Site | Isehara | Kanagawa |
Japan | Novartis Investigative Site | Kagoshima-city | Kagoshima |
Japan | Novartis Investigative Site | Kitaadachi-gun | Saitama |
Japan | Novartis Investigative Site | Kumamoto City | Kumamoto |
Japan | Novartis Investigative Site | Maebashi city | Gunma |
Japan | Novartis Investigative Site | Matsuyama | Ehime |
Japan | Novartis Investigative Site | Minato ku | Tokyo |
Japan | Novartis Investigative Site | Nagoya | Aichi |
Japan | Novartis Investigative Site | Osaka-city | Osaka |
Japan | Novartis Investigative Site | Osaka-city | Osaka |
Japan | Novartis Investigative Site | Sapporo-city | Hokkaido |
Japan | Novartis Investigative Site | Yokohama-city | Kanagawa |
Korea, Republic of | Novartis Investigative Site | Bundang Gu | Gyeonggi Do |
Korea, Republic of | Novartis Investigative Site | Gyeonggi do | Korea |
Korea, Republic of | Novartis Investigative Site | Seoul | Korea |
Korea, Republic of | Novartis Investigative Site | Seoul | |
Korea, Republic of | Novartis Investigative Site | Seoul | |
Korea, Republic of | Novartis Investigative Site | Seoul | |
Lebanon | Novartis Investigative Site | Ashrafieh | |
Lebanon | Novartis Investigative Site | Beirut | |
Lebanon | Novartis Investigative Site | Saida | |
Mexico | Novartis Investigative Site | Monterrey NL | Monterrey |
Mexico | Novartis Investigative Site | San Luis Potosi | |
Netherlands | Novartis Investigative Site | Terneuzen | |
Netherlands | Novartis Investigative Site | Venray | CE |
Peru | Novartis Investigative Site | Lima | |
Peru | Novartis Investigative Site | San Borja | Lima |
Peru | Novartis Investigative Site | Surquillo | Lima |
Romania | Novartis Investigative Site | Craiova | Dolj |
Romania | Novartis Investigative Site | Floresti | Cluj |
Romania | Novartis Investigative Site | Iasi | |
Russian Federation | Novartis Investigative Site | Arkhangelsk | |
Russian Federation | Novartis Investigative Site | Ryazan | |
Russian Federation | Novartis Investigative Site | St Petersburg | |
Spain | Novartis Investigative Site | Alicante | Comunidad Valenciana |
Spain | Novartis Investigative Site | Badajoz | Extremadura |
Spain | Novartis Investigative Site | Badalona | Catalunya |
Spain | Novartis Investigative Site | Barcelona | Cataluna |
Spain | Novartis Investigative Site | Caceres | Extremadura |
Spain | Novartis Investigative Site | Castellon | Comunidad Valenciana |
Spain | Novartis Investigative Site | El Palmar | Murcia |
Spain | Novartis Investigative Site | Jerez | Cadiz |
Spain | Novartis Investigative Site | La Laguna | Santa Cruz De Tenerife |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Palma De Mallorca | Islas Baleares |
Spain | Novartis Investigative Site | Pozuelo de Alarcon | Madrid |
Spain | Novartis Investigative Site | Santiago de Compostela | Galicia |
Spain | Novartis Investigative Site | Sevilla | Andalucia |
Spain | Novartis Investigative Site | Valencia | Comunidad Valenciana |
Sweden | Novartis Investigative Site | Gavle | |
Sweden | Novartis Investigative Site | Oerebro | |
Sweden | Novartis Investigative Site | Vasteras | |
Taiwan | Novartis Investigative Site | Taipei | |
Taiwan | Novartis Investigative Site | Taipei | |
Thailand | Novartis Investigative Site | Bangkok | THA |
Thailand | Novartis Investigative Site | Bangkok | |
United Kingdom | Novartis Investigative Site | Leicester | |
United Kingdom | Novartis Investigative Site | London | |
United Kingdom | Novartis Investigative Site | Plymouth | Devon |
United States | Mercy Medical Center SC-2 | Baltimore | Maryland |
United States | Beverly Hills Cancer Center | Beverly Hills | California |
United States | St Vincent Frontier Cancer Center | Billings | Montana |
United States | Massachusetts General Hospital Updated Regulatory | Boston | Massachusetts |
United States | Lahey Clinic | Burlington | Massachusetts |
United States | Ironwood Cancer and Research Centers Chandler 2 | Chandler | Arizona |
United States | Rush University Medical Center Rush Uni Medical Center | Chicago | Illinois |
United States | University Hospitals of Cleveland Seidman Cancer Center SC | Cleveland | Ohio |
United States | Good Samaritan Regional Medical Center Good Samaritan Reg Med Ctr | Corvallis | Oregon |
United States | Texas Oncology PA Dallas Presbyterian Hospital SC-1 | Dallas | Texas |
United States | City of Hope National Medical Center | Duarte | California |
United States | El Paso, Texas Oncology | El Paso | Texas |
United States | NorthShore University Health System NorthShore University | Evanston | Illinois |
United States | Virginia Cancer Specialists SC | Fairfax | Virginia |
United States | Highlands Oncology Group | Fayetteville | Arkansas |
United States | Florida Cancer Specialists FL Cancer Specialists | Fort Myers | Florida |
United States | Fort Wayne Medical Oncology/Hematology, Inc. Dept.of Fort Wayne Med Onc/Hem | Fort Wayne | Indiana |
United States | Prisma Health Upstate SC-2 | Greenville | South Carolina |
United States | St. Luke's Cancer Institute SC | Kansas City | Missouri |
United States | Scripps Clinic SC | La Jolla | California |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Edward Cancer Center SC | Naperville | Illinois |
United States | Tennessee Oncology SC-3 | Nashville | Tennessee |
United States | Rutgers Cancer Institute of New Jersey SC-2 | New Brunswick | New Jersey |
United States | Detroit Clinical Research Center | Owosso | Michigan |
United States | Florida Cancer Specialists-North SC | Saint Petersburg | Florida |
United States | Mays Cancer Ctr Uthsa Mdacc InstituteForDrugDevelopment(4) | San Antonio | Texas |
United States | Kaiser Permanente - California Southern | San Diego | California |
United States | University of California San Francisco | San Francisco | California |
United States | Mayo Clinic - Arizona | Scottsdale | Arizona |
United States | Avera Cancer SC | Sioux Falls | South Dakota |
United States | St. Francis Health Comprehensive Cancer Center SC | Topeka | Kansas |
United States | Texas Oncology Northeast Texas | Tyler | Texas |
United States | Wenatchee Valley Medical Center SC-2 | Wenatchee | Washington |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Lebanon, Mexico, Netherlands, Peru, Romania, Russian Federation, Spain, Sweden, Taiwan, Thailand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort | PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS will be assessed via a local radiology assessment according to RECIST 1.1 | Once approximately 243 PFS events in this cohort had been observed, up to 32 months | |
Secondary | Overall Survival (OS) for Patients With PI3KCA Mutant Status | OS is defined as the time from date of randomization to date of death due to any cause. | Up to approximatly 59 months | |
Secondary | Overall Response Rate (ORR) | ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST 1.1. | Up to approximatly 36 months | |
Secondary | Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status | Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) | Baseline, Up to approximatly 36 months | |
Secondary | Safety and Tolerability of Alpelisib in Combination With Fulvestrant | Safety will be determined by type, frequency and severity of adverse events per CTCAEv4.03 and type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study. | Up to approximatly 37 months | |
Secondary | Time to 10% Deterioration in the Global Health Status/Quality of Life (QOL) Scale Score of the EORTC QLQ-C30 | Composite measure of change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment will be summarized | Up to approximatly 36 months | |
Secondary | Plasma Concentration-time Profile of Alpelisib Given in Combinatio With Fulvestrant and Appropriate Pharmacokinetics (PK) Parameters | Assessment of any potential impact of fulvestrant on the pharmacokinetics of alpelisib by collection of sparse and trough PK samples. PK parameters includes,but not limited to, Cmin, Cmax, t1/2, AUClast for alpelisib (and any relevant metabolites) and fulvestrant | Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2,4, 6, 8 | |
Secondary | PFS Based on Radiology Assessments and Using RECIST 1.1 Criteria | PFS in patients with PIK3CA mutant status and patients with PIK3CA non-mutant status as measured in ctDNA. | Baseline, Up to approximatly 36 months | |
Secondary | Clinical Benefit Rate (CBR) | Clinical benefit rate is defined as the proportion of patients with a best overall response of CR or PR or SD or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment. | Up to approximatly 36 months | |
Secondary | Change in the Global Health Status/(QOL) Scale Score of the EORTC QLQ-C30 | Composite measure of change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment will be summarized | Baseline, Up to approximatly 36 months | |
Secondary | Summary Statistics of Fulvestrant and Alpelisib Plasma Concentrations | Assessment of any potential impact of fulvestrant on the pharmacokinetics of alpelisib by collection of sparse and trough PK samples. | Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2,4, 6, 8 | |
Secondary | PFS for Patients With PIK3CA Non-mutant Status | PFS based on local radiology assessments and using RECIST 1.1 criteria in the PIK3CA non-mutant cohort | Up to approximatly 36 months | |
Secondary | OS for Patients With PIK3CA Non-mutant Status | OS is defined as the time from date of randomization to date of death due to any cause. | Up to approximatly 59 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |